Takeda to commercialize Teva’s PD drug rasagiline in Japan

29 April 2014

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has entered an agreement allowing to commercialize Israel-based Teva Pharmaceutical Industries’ (NYSE: TEVA) innovative treatment for Parkinson’s disease, rasagiline in Japan.

Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan. Under the terms of the accord, Takeda will develop rasagiline tablets for the Japanese market and submit a New Drug Application for registration of the product in Japan. Financial details of the deal are confidential.

Adds to deal for Copaxone

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK